Canadian health officials are calling for immediate vaccination as the respiratory virus season appears to be arriving ahead of schedule. The National Advisory Committee on Immunization (NACI) has released specific guidance for flu, COVID-19, and RSV protection to mitigate early surges across the country.
McMaster's Dawn Bowdish warns of an early epidemic surge
Immunologist Dawn Bowdish, who leads the Firestone Institute for Respiratory Health at McMaster University, suggests that the current season is trending toward an early peak. According to the report, Bowdish noted that the country may soon "tick up into the epidemic range," making immediate vaccination critical to avoid being caught unprotected.
Because it takes approximately two weeks for the body to develop immunity after a shot, health experts emphasize that waiting until peak infection periods may be too late. bowdish also highlighted a concerning decline in flu vaccination rates among children since the pandemic, noting that even healthy children face significant risks from the virus, particularly those with asthma .
H1N1's emergence and the shift from last year's H3N2
Early data from the Public Health Agency of Canada indicates that the H1N1 influenza A type is currently circulating in various parts of the country. this marks a notable shift from the previous year, when the H3N2 strain was the dominant influenza A type in Canada.
The distinction between these strains is clinically significant, as Bowdish noted that H3N2 typically impacts older adults and long-term care facilities more severely, while H1N1 often presents more serious complications in children. Dr. winnie Siu, a senior medical adviser for NACI, noted that while last year's vaccine was not a perfect match, it still provided 40 per cent protection against the need for hospitalization.
Nirsevimab and the strategy for high-risk infants
Respiratory syncytial virus (RSV) remains a primary concern for pediatric health, as it is the leading cause of bronchiolitis and pneumonia in young children. To combat this, NACI recommends the use of ready-made antibodies, specifically nirsevimab or clesrovimab, for infants during their first RSV season .
Dr. Elissa Abrams, a pediatrics specialist and NACI adviser, specified that high-risk infants—including those born prematurely or those with Down syndrome—require these protections. Additionally, adults aged 75 and older, along with certain high-risk adults aged 65 to 74, are encouraged to seek RSV vaccination to prevent severe illness.
Protecting the 65-plus demographic from XFG Omicron strains
The current COVID-19 vaccine is designed to target the XFG strain, which is a subtype of the Omicron variant.. Nicole Forbes, the technical lead on COVID-19 for NACI, emphasized that age remains the most significant risk factor for severe illness, with seniors accounting for the majority of hospitalizations and deaths.
NACI's recommendations include a second annual dose for individuals aged 80 and older, as well as those in long-term care or living with underlying medical conditions. While the vaccine targets the XFG subtype, experts expect the illness pattern to remain similar to previous Omicron subvariants.
The uncertainty of provincial funding for COVID-19 shots
Despite the clear medical recommendations from NACI, several logistical questions remain regarding the accessibility of these vaccines. One major unknown is whether every province and territory will choose to publicly fund the COVID-19 vaccine for the general public, as the committee's recommendation for those aged six months and older is subject to regional government decisions.
Furthermore, while H1N1 is currently circulating, it remains unverified whether it will become the primary dominant strain for the entire season, as data from the Southern Hemisphere suggests H3N2 could still play a significant role in the overall epidemic landscape.
Comments 0